Voyager Therapeutics VYGR
NASDAQ VYGR
$1.76 -0.07 (-3.56%)
At close: Nov 11, 2026 · 4:00 PM EST

Voyager Therapeutics (VYGR) Gains from Sales and Divestitures (2023 - 2026)

Updated

Voyager Therapeutics' Gains from Sales and Divestitures came in at -$62,000 for Q4 2025, compared with -$32,000 a year earlier.

Analysis

Voyager Therapeutics (VYGR) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends

For FY2025, Voyager Therapeutics' Gains from Sales and Divestitures was -$141,000.

  • Going back by year, Gains from Sales and Divestitures was -$510,000 in FY2024, -$178,000 in FY2023 and -$377,000 in FY2022.
  • The Q4 2025 figure represents the lowest quarterly Gains from Sales and Divestitures since Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Voyager Therapeutics 113.78 Mn -447.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -577,000.00
Dec 31, 2025 -62,000.00
Jun 30, 2025 -49,000.00
Mar 31, 2025 -30,000.00
Dec 31, 2024 -32,000.00
Sep 30, 2024 -192,000.00
Jun 30, 2024 -227,000.00
Mar 31, 2024 -59,000.00
Dec 31, 2023 -35,000.00
Sep 30, 2023 -19,000.00
Jun 30, 2023 -80,000.00
Mar 31, 2023 -44,000.00
API Access

Voyager Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=VYGR&period=max&api_key=YOUR_API_KEY